Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Previous studies of raloxifene conducted in animal models and postmenopausal women have demonstrated antiestrogenic action on the endometrium. The purpose of this first study of raloxifene in women with normal menstrual cycles was to determine its reproductive endocrine and endometrial effects. In part I, raloxifene (400 mg) was administered for 5 days in the follicular, periovulatory, or luteal phase of the menstrual cycle (n = 12). In part II, women were randomized to receive raloxifene (100 or 200 mg) for 28 days beginning on day 3 of the cycle (n = 19). All women ovulated in both parts of the study. Raloxifene did not alter the length of the menstrual cycle or the day of the LH surge. A 5-day course of raloxifene administered in any phase of the cycle elevated FSH area under the curve (AUC) for the entire cycle and estradiol AUC for the second half of the cycle compared with those in control cycles. In part II, raloxifene also appeared to increase the FSH AUC and estradiol AUC. Raloxifene decreased the number of gland mitoses in follicular phase endometrial biopsies. Subtle effects suggestive of gland-stromal dysynchrony were noted in a limited number of the secretory phase endometrial biopsies. This study has demonstrated that 1) raloxifene does not prevent ovulation in women with normal menstrual cycles; 2) ovarian estrogen production will continue, and in some cases increase, in response to raloxifene; and 3) antiestrogenic effects of raloxifene on the endometrium are subtle in the endocrine milieu of normal to high circulating estradiol concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clomiphene citrate: mechanism(s) and site(s) of action—a hypothesis revisited
Wallach, E. E., & Adashi, E. Y. (1984) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48069-6 · Cited by 249
Dickey, R. P., Olar, T. T., Taylor, S. N., Curole, D. N., & Matulich, E. M. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55855-5 · Cited by 171
Cited by
Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications
Stratton, P., & Berkley, K. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq050 · Cited by 442
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*
Jordan, V. C., & Morrow, M. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0368 · Cited by 258
A pharmacological review of selective oestrogen receptor modulators
Goldstein, S. R. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.212 · Cited by 205
Chlebowski, R. T., Collyar, D. E., Somerfield, M. R., & Pfister, D. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1939 · Cited by 164
Stratton, P., Sinaii, N., Segars, J., Koziol, D., Wesley, R., Zimmer, C., Winkel, C., & Nieman, L. K. (2008) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000297307.35024.b5 · Cited by 140
Metadata
- Authors
- Baker, V. L., Draper, M., Paul, S., Allerheiligen, S., Glant, M., Shifren, J., & Jaffe, R. B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-01-01
- Volume
- 83
- Issue
- 1
- Pages
- 6-13
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2005756271
- Cited by
- 95
- References
- 2
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1. https://app.cochat.ai/papers/10.1210/jcem.83.1.4448
- The paper
- Baker, V. L., Draper, M., Paul, S., Allerheiligen, S., Glant, M., Shifren, J., & Jaffe, R. B. (1998). Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.83.1.4448
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.